Clinical Trial Update: Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) [Phase 2]

View source ↗

Summary

A Phase 2 trial (OMNIVORE) is evaluating optimized management of nivolumab based on patient response in advanced renal cell carcinoma; the study is currently no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Toni Choueiri, MD | Conditions: Renal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-04-25